1. Home
  2. ECPG vs MIRM Comparison

ECPG vs MIRM Comparison

Compare ECPG & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Encore Capital Group Inc

ECPG

Encore Capital Group Inc

HOLD

Current Price

$72.52

Market Cap

1.4B

Sector

Finance

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$96.17

Market Cap

5.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ECPG
MIRM
Founded
1998
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
5.7B
IPO Year
1999
2019

Fundamental Metrics

Financial Performance
Metric
ECPG
MIRM
Price
$72.52
$96.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
12
Target Price
$77.33
$115.33
AVG Volume (30 Days)
218.8K
833.2K
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
287.14
74.59
EPS
10.91
N/A
Revenue
$1,768,802,000.00
$19,138,000.00
Revenue This Year
$4.53
$26.22
Revenue Next Year
$4.76
$21.77
P/E Ratio
$6.65
N/A
Revenue Growth
34.37
N/A
52 Week Low
$26.45
$36.88
52 Week High
$74.58
$109.28

Technical Indicators

Market Signals
Indicator
ECPG
MIRM
Relative Strength Index (RSI) 66.25 57.29
Support Level $53.81 $85.35
Resistance Level $74.58 $96.65
Average True Range (ATR) 2.13 4.11
MACD -0.11 0.90
Stochastic Oscillator 94.68 90.61

Price Performance

Historical Comparison
ECPG
MIRM

About ECPG Encore Capital Group Inc

Encore Capital Group Inc is an international specialty finance company engaged in providing debt recovery solutions and other related services for consumers across a broad range of financial assets. It mainly purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals to repay their obligations and work toward financial recovery. The company also provides debt servicing and other portfolio management services to credit originators for non-performing loans in Europe. It has only one reportable segment, debt purchasing and recovery. Geographically, the company generates maximum revenue from its business in the United States, followed by the United Kingdom, Europe, and other regions.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

Share on Social Networks: